Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$48.37 USD
-0.48 (-0.98%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $48.17 -0.20 (-0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKRO 48.37 -0.48(-0.98%)
Will AKRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKRO
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Other News for AKRO
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade)
Insider Sell: Andrew Cheng Sells 30,000 Shares of Akero Therapeutics Inc (AKRO)
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Target | AKRO Stock News